1-acetyl-3-(triphenylphosphanylidine)pyrrolidin-2-one | 249736-46-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-acetyl-3-(triphenylphosphanylidine)pyrrolidin-2-one
• 英文别名: 1-acetyl-3-(triphenyl-phosphanylidene)-pyrrolidin-2-one；1-Acetyl-3-(triphenylphosphoranylidene)-2-pyrrolidinone；1-acetyl-3-(triphenyl-λ5-phosphanylidene)pyrrolidin-2-one
• CAS: 249736-46-7
• 化学式: C₂₄H₂₂NO₂P
• 分子量: 387.418
• InChiKey: XMJMCOOPDQXHNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-acetyl-3-(triphenylphosphanylidine)pyrrolidin-2-one 在 四丁基氟化铵 、 二异丁基氢化铝 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  Structure-Based Design of a Parallel Synthetic Array Directed Toward the Discovery of Irreversible Inhibitors of Human Rhinovirus 3C Protease

  摘要：

  Utilizing the tools of parallel synthesis and structure-based design, a new class of Michael acceptor-containing, irreversible inhibitors of human rhinovirus 3C protease (HRV 3CP) was discovered. These inhibitors are shown to inhibit HRV-14 3CP with rates of inactivation ranging from 886 to 31400 M-1 sec(-1). These inhibitors exhibit antiviral activity when tested against HRV-14 infected H1-HeLa cells, with EC50 values ranging from 1.94 to 0.15 muM. No cytotoxicity was observed at the limits of the assay concentration. A crystal structure of one of the more potent inhibitors covalently bound to HRV-2 3CP is detailed, These compounds were also tested against HRV serotypes other than type 14 and were found to have highly variable activities.

  DOI：

  10.1021/jm010435c
• 作为产物：
  描述：

  1-acetyl-3-bromo-pyrrolidin-2-one 在 sodium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 8.0h， 生成 1-acetyl-3-(triphenylphosphanylidine)pyrrolidin-2-one
  参考文献：
  名称：

  Structure-Based Design of a Parallel Synthetic Array Directed Toward the Discovery of Irreversible Inhibitors of Human Rhinovirus 3C Protease

  摘要：

  Utilizing the tools of parallel synthesis and structure-based design, a new class of Michael acceptor-containing, irreversible inhibitors of human rhinovirus 3C protease (HRV 3CP) was discovered. These inhibitors are shown to inhibit HRV-14 3CP with rates of inactivation ranging from 886 to 31400 M-1 sec(-1). These inhibitors exhibit antiviral activity when tested against HRV-14 infected H1-HeLa cells, with EC50 values ranging from 1.94 to 0.15 muM. No cytotoxicity was observed at the limits of the assay concentration. A crystal structure of one of the more potent inhibitors covalently bound to HRV-2 3CP is detailed, These compounds were also tested against HRV serotypes other than type 14 and were found to have highly variable activities.

  DOI：

  10.1021/jm010435c

文献信息

• Protease inhibitors
  申请人：Yang Syaulan

  公开号：US20050143319A1

  公开（公告）日：2005-06-30

  This invention relates to treating an infection with a virus using protease inhibitors. Examples of the protease inhibitors include compounds of formula (I). Each variable is defined in the specification.

  这项发明涉及使用蛋白酶抑制剂治疗病毒感染。蛋白酶抑制剂的示例包括公式(I)的化合物。每个变量在说明书中有定义。
• [EN] LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2<br/>[FR] DÉRIVÉS DE PYRIMIDINE À FUSION HÉTÉROARYLE LACTAME SERVANT D'INHIBITEURS D'ERBB2
  申请人：ENLIVEN THERAPEUTICS INC

  公开号：WO2022140769A1

  公开（公告）日：2022-06-30

  The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.

  本公开涉及抑制ErbB2的化合物及其组合物，包括突变形式的ErbB2，特别是那些携带Exon 20突变的形式，制备这些化合物和组合物的方法，以及它们在治疗或预防各种癌症方面的用途，如肺癌、胶质瘤、皮肤癌、头颈癌、唾液腺癌、乳腺癌、食管癌、肝癌、胃癌、子宫癌、宫颈癌、胆道癌、胰腺癌、结肠直肠癌、肾癌、膀胱癌或前列腺癌。
• Structure-Based Design of a Parallel Synthetic Array Directed Toward the Discovery of Irreversible Inhibitors of Human Rhinovirus 3C Protease
  作者：Theodore O. Johnson、Ye Hua、Hiep T. Luu、Edward L. Brown、Fora Chan、Shao Song Chu、Peter S. Dragovich、Brian W. Eastman、Rose Ann Ferre、Shella A. Fuhrman、Thomas F. Hendrickson、Fausto C. Maldonado、David A. Matthews、James W. Meador、Amy K. Patick、Siegfried H. Reich、Donald J. Skalitzky、Stephen T. Worland、Michelle Yang、Leora S. Zalman

  DOI：10.1021/jm010435c

  日期：2002.5.1

  Utilizing the tools of parallel synthesis and structure-based design, a new class of Michael acceptor-containing, irreversible inhibitors of human rhinovirus 3C protease (HRV 3CP) was discovered. These inhibitors are shown to inhibit HRV-14 3CP with rates of inactivation ranging from 886 to 31400 M-1 sec(-1). These inhibitors exhibit antiviral activity when tested against HRV-14 infected H1-HeLa cells, with EC50 values ranging from 1.94 to 0.15 muM. No cytotoxicity was observed at the limits of the assay concentration. A crystal structure of one of the more potent inhibitors covalently bound to HRV-2 3CP is detailed, These compounds were also tested against HRV serotypes other than type 14 and were found to have highly variable activities.